A recent paper identified the ubiquitin ligase TRIM37 as responsible for cancer-specific vulnerability to PLK4 inhibition [105], and identification of vulnerability hot spots could help PLK4 targeting in cancers. This evidence concerns the gene PLK4 and cancer.